Analysis of statistics of pancreatic cancer in Ukraine for a period of 10 years.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16721-e16721
Author(s):  
Liliia Zrielykh
Keyword(s):  
Pancreatic Cancer ◽  
Health Financing ◽  
Cancer Registries ◽  
Special Treatment ◽  
Number Of Patients ◽  
Incidence And Mortality ◽  
World Standard ◽  
Access To Medical Care ◽  
Low Coverage ◽  
Medical Examinations

e16721 Background: Pancreatic cancer (PC) is the 7th leading cause of cancer death in both sexes and 12th most common cancer worldwide. The estimated 5-year survival rate for it is nearly 5% both in developed and in developing countries. Methods: Analysis of data of National and regional cancer registries. Results: Number of new PC cases in 2003 in Ukraine was 4837 ( men – 2666, women – 2171), in 2013 – 5296 ( men – 2877, women – 2419). So the number of PC cases increased by 8,7% ( by 7,3% in men, by 10,3% in women) in 2013 in comparison to 2003. Number of deaths from PC in 2003 was 4115 (men – 2291, women – 1824), in 2013 – 4307 ( men – 2328, women – 1979). The number of PC deaths increased by 4,5% ( by 1,6% in men, by 7,8% in women). Incidence of PC in children population (age 0-17 years) in 2003 was 0, in 2013 – 4 ( men – 0, women – 4). Age-standardised incidence rate (world standard) of PC in 2003 was 5,9 ( 8,6 in men; 4,0 in women), in 2013 – 6,8 ( 9,8 in men; 4,7 in women). Age-standardised mortality rate (world standard) in 2003 was 5,0 ( men – 7,4; women – 3,4), in 2013 – 5,5 ( men – 7,9; women – 3,9). Patients diagnosed during the preventive medical examinations in 2003 were 3.8% ( men – 3,6%, women – 4,1%), in 2013 - 3.2% ( men – 3,2%, women – 3,3%). Newly diagnosed patients received the special treatment in 2003 were 27,6% (men – 28,7%, women – 26,1%), in 2013 - 26% (men – 25,5%, women – 26,6%). From among them surgical treatment only received 60.8% in 2003, 45.9% in 2013, Combined or complex scheme of treatment received 10.1% in 2003, 10.5% in 2013. The percentage of histologically verified PC in 2003 – 28,4%, in 2013 was 33,6%. Conclusions: There is a tendency of increase of incidence and mortality rates of PC in Ukraine. There have been cases of morbidity in children in 2013 compared with 2003. The number of patients revealed during preventive medical examinations remains low in 2013 and in 2003 due to low health financing, low coverage of preventive medical examinations. The number of patients who received special treatment remains low during 10 years. This is mainly due to lack of access to medical care, high cost of treatment, diagnosis of PC at an advanced stage.

Analysis of statistical indicators of the population of Saint Petersburg with malignant neoplasms of pancreas

2021 ◽  
Vol 23 (2) ◽  
pp. 155-164
Author(s):  
Vladislav E. Moiseenko ◽  
Alexander V. Pavlovsky ◽  
Dmitry A. Granov ◽  
Larisa V. Kochorova ◽  
Inna V. Dodonova ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Stage Iv ◽  
Malignant Neoplasms ◽  
Number Of Patients ◽  
Incidence And Mortality ◽  
Significant Downward Trend ◽  
Accumulation Index ◽  
One Year ◽  
The One ◽  
Statistical Indicators

Morbidity and mortality from pancreatic cancer is an urgent medical and social problem. Evaluation of statistical indicators in dynamics makes it possible to identify organizational and clinical problems in providing care to patients with malignant neoplasms of the pancreas. Medical and statistical indicators of incidence of malignant pancreatic neoplasms in St. Petersburg residents are evaluated. The assessment of medical and statistical indicators of the incidence of malignant neoplasms of the pancreas in residents of St. Petersburg. Statistical data were studied for the period from 2014 to 2019. The increase in the "rough" indicator of primary morbidity changed from 417.99 per 100 thousand population in 2014 to 505.6 in 2019. In the structure of primary cancer incidence, the indicator of active detection of pancreatic cancer glands in 2014 amounted to 3.6%, in 2019 3.8%. The proportion of patients with diagnoses confirmed morphologically increased from 48.9% to 61.4%. The proportion of patients with newly diagnosed stage IV of the disease changed from 39.5% in 2014 to 51.4% in 2019, and in patients with stage III in 2019 it was 33.3% (a decrease in comparison with 2014 15.3%). In 2019, the disease was diagnosed at stage II in 15.2% of patients. The proportion of patients with stage I in 2019 was 6.6%, this indicator in 2014 was registered at the level of 19.2%. From 2014 to 2019, the one-year mortality rate did not change and amounted to 67.9 and 67.4%, respectively (the decrease was 0.7%). Over the past 5 years, there has been no significant downward trend in the "rough" incidence and mortality rates from pancreatic cancer. However, in the dynamics, there was an increase in the number of patients registered for 5 or more years, and an increase in the accumulation index of the contingent of patients with pancreatic cancer.

Trends in the incidence and mortality of oral cancer in Nevada (Preprint)

2020 ◽  
Author(s):  
Kevin Foote ◽  
Karl Kingsley
Keyword(s):  
Public Health ◽  
Oral Cancer ◽  
Cancer Incidence ◽  
Cancer Control ◽  
Cancer Registries ◽  
Public Health Research ◽  
Chi Square ◽  
Incidence And Mortality ◽  
The Us ◽  
Chi Square Analysis

BACKGROUND Reviews of national and state-specific cancer registries have revealed differences in rates of oral cancer incidence and mortality that have implications for public health research and policy. Many significant associations between head and neck (oral) cancers and major risk factors, such as cigarette usage, may be influenced by public health policy such as smoking restrictions and bans – including the Nevada Clean Indoor Act of 2006 (and subsequent modification in 2011). OBJECTIVE Although evaluation of general and regional advances in public policy have been previously evaluated, no recent studies have focused specifically on the changes to the epidemiology of oral cancer incidence and mortality in Nevada. METHODS Cancer incidence and mortality rate data were obtained from the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) Surveillance, Epidemiology and End Results (SEER) program. Most recently available rate changes in cancer incidence and mortality for Nevada included the years 2012 – 2016 and are age-adjusted to the year 2000 standard US population. Comparisons of any differences between Nevada and the overall US population were evaluated using Chi square analysis. RESULTS This analysis revealed that the overall rates of incidence and mortality from oral cancer in Nevada differs from that observed in the overall US population. For example, although the incidence of oral cancer among Caucasians is increasing in Nevada and the US overall, it is increasing at nearly twice that rate in Nevada, P=0.0002. In addition, although oral cancer incidence among Minorities in the US is declining, it is increasing in Nevada , P=0.0001. Analysis of reported mortality causes revealed that mortality from oral cancer increased in the US overall but declined in Nevada during the same period (2012-2016). More specifically, mortality among both Males and Females in the US is increasing, but is declining in Nevada, P=0.0027. CONCLUSIONS Analysis of the epidemiologic data from Nevada compared with the overall US revealed significant differences in rates of oral cancer incidence and mortality. More specifically, oral cancer incidence increased in Nevada between 2012-2016 among all groups analyzed (Males, Females, White, Minority), while decreases were observed nationally among Females and Minorities. Although mortality in Nevada decreased over this same time period (in contrast to the national trends), the lag time between diagnosis (incidence) and mortality suggests that these trends will change in the near future. CLINICALTRIAL Not applicable

scholarly journals Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries

Cancers ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 141
Author(s):  
Junjie Huang ◽  
Anastasios Koulaouzidis ◽  
Wojciech Marlicz ◽  
Veeleah Lok ◽  
Cedric Chu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Esophageal Cancer ◽  
The Netherlands ◽  
Cancer Registries ◽  
Global Burden ◽  
Annual Percent Change ◽  
The United Kingdom ◽  
Incidence And Mortality ◽  
Elevated Cholesterol ◽  
Prevalence Of Obesity

This study aimed to examine the global burden, risk factors, and trends of esophageal cancer based on age, sex, and histological subtype. The data were retrieved from cancer registries database from 48 countries in the period 1980–2017. Temporal patterns of incidence and mortality were evaluated by average annual percent change (AAPC) using joinpoint regression. Associations with risk factors were examined by linear regression. The highest incidence of esophageal cancer was observed in Eastern Asia. The highest incidence of adenocarcinoma (AC) was found in the Netherlands, the United Kingdom, and Ireland. A higher AC/squamous cell carcinoma (SCC) incidence ratio was associated with a higher prevalence of obesity and elevated cholesterol. We observed an incidence increase (including AC and SCC) in some countries, with the Czech Republic (female: AAPC 4.66), Spain (female: 3.41), Norway (male: 3.10), Japan (female: 2.18), Thailand (male: 2.17), the Netherlands (male: 2.11; female: 1.88), and Canada (male: 1.51) showing the most significant increase. Countries with increasing mortality included Thailand (male: 5.24), Austria (female: 3.67), Latvia (male: 2.33), and Portugal (male: 1.12). Although the incidence of esophageal cancer showed an overall decreasing trend, an increasing trend was observed in some countries with high AC/SCC incidence ratios. More preventive measures are needed for these countries.

scholarly journals Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?

Medicina ◽  
2021 ◽  
Vol 57 (1) ◽  
pp. 77
Author(s):  
Nathalie Rosumeck ◽  
Lea Timmermann ◽  
Fritz Klein ◽  
Marcus Bahra ◽  
Sebastian Stintzig ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Neoadjuvant Therapy ◽  
Induction Therapy ◽  
Locally Advanced ◽  
Eastern Cooperative Oncology Group ◽  
Advanced Pancreatic Cancer ◽  
Comprehensive Cancer Center ◽  
Secondary Resection ◽  
Number Of Patients

Background and Objectives: An increasing number of patients (pts) with locally advanced pancreatic cancer (LAPC) are treated with an intensive neoadjuvant therapy to obtain a secondary curative resection. Only a certain number of patients benefit from this intention. The aim of this investigation was to identify prognostic factors which may predict a benefit for secondary resection. Materials and Methods: Survival time and clinicopathological data of pts with pancreatic cancer were prospective and consecutively collected in our Comprehensive Cancer Center Database. For this investigation, we screened for pts with primarily unresectable pancreatic cancer who underwent a secondary resection after receiving induction therapy in the time between March 2017 and May 2019. Results: 40 pts had a sufficient database to carry out a reliable analysis. The carbohydrate-antigen 19-9 (CA 19-9) level of the pts treated with induction therapy decreased by 44.7% from 4358.3 U/mL to 138.5 U/mL (p = 0.001). The local cancer extension was significantly reduced (p < 0.001), and the Eastern Cooperative Oncology Group (ECOG) performance status was lowered (p = 0.03). The median overall survival (mOS) was 20 months (95% CI: 17.2–22.9). Pts who showed a normal CA 19-9 level (<37 U/mL) at diagnosis and after neoadjuvant therapy or had a Body Mass Index (BMI) below 25 kg/m2 after chemotherapy had a significant prolonged overall survival (29 vs. 19 months, p = 0.02; 26 vs. 18 months, p = 0.04; 15 vs. 24 months, p = 0.01). Pts who still presented elevated CA 19-9 levels >400 U/mL after induction therapy did not profit from a secondary resection (24 vs. 7 months, p < 0.001). Nodal negativity as well as the performance of an adjuvant therapy lead to better mOS (25 vs. 15 months, p = 0.003; 10 vs. 25 months, p < 0.001). Conclusion: The pts in our investigation had different benefits from the multimodal treatment. We identified the CA 19-9 level at time of diagnosis and after neoadjuvant therapy as well as the preoperative BMI as predictive factors for overall survival. Furthermore, diagnostics of presurgical nodal status should gain more importance as nodal negativity is associated with better outcome.

Trends in stomach and pancreatic cancer incidence and mortality in England and Wales, 1951-2000

2007 ◽  
Vol 94 (9) ◽  
pp. 1162-1171 ◽  
Author(s):  
D. Fitzsimmons ◽  
C. Osmond ◽  
S. George ◽  
C. D. Johnson
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Incidence ◽  
England And Wales ◽  
Incidence And Mortality

scholarly journals Managing older adults’ fear of coronavirus disease: A new role for social work practice

2020 ◽  
pp. 147332502097329
Author(s):  
Hamed Mortazavi
Keyword(s):  
Older Adults ◽  
Case Fatality Rate ◽  
Severe Disease ◽  
Case Fatality ◽  
Social Work Practice ◽  
World Health ◽  
National Committee ◽  
Fatality Rate ◽  
Number Of Patients ◽  
Incidence And Mortality

As the number of patients infected with the 2019 novel coronavirus disease (nCOVID-19) increases, the number of deaths has also been increasing. According to World Health Organization (WHO), as of 4 October 2020, 34,804,348 cases had tested positive for nCOVID-19 globally, which among them, 1,030,738 confirmed deaths had occurred, equivalent to a case-fatality rate of 2.96%. However, in comparison with global statistics, the incidence and mortality of the nCOVID-19 infection are higher in Iran. As reported by the National Committee on COVID-19 Epidemiology of Ministry of Health of Iran, the total number of patients with confirmed COVID-19 infection has reached 468,119, of which 26,746 have died, equivalent to a case-fatality rate of 5.71%. Currently, there is solid evidence that older adults are at a higher risk of severe disease following infection from COVID-19.

scholarly journals Potato consumption and risk of pancreatic cancer in the HELGA cohort

2018 ◽  
Vol 119 (12) ◽  
pp. 1408-1415
Author(s):  
Lene A. Åsli ◽  
Tonje Braaten ◽  
Anja Olsen ◽  
Anne Tjønneland ◽  
Kim Overvad ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Registries ◽  
Glycaemic Index ◽  
Proportional Hazard ◽  
Cox Proportional Hazard ◽  
Cox Proportional Hazard Models ◽  
The Mean ◽  
Potato Consumption ◽  
Adjusted Model

AbstractPotatoes have been a staple food in many countries throughout the years. Potatoes have a high glycaemic index (GI) score, and high GI has been associated with several chronic diseases and cancers. Still, the research on potatoes and health is scarce and contradictive, and we identified no prospective studies that had investigated the association between potatoes as a single food and the risk of pancreatic cancer. The aim of this study was to prospectively investigate the association between potato consumption and pancreatic cancer among 114 240 men and women in the prospective HELGA cohort, using Cox proportional hazard models. Information on diet (validated FFQ’s), lifestyle and health was collected by means of a questionnaire, and 221 pancreatic cancer cases were identified through cancer registries. The mean follow-up time was 11·4 (95 % CI 0·3, 16·9) years. High consumption of potatoes showed a non-significantly higher risk of pancreatic cancer in the adjusted model (hazard ratio (HR) 1·44; 95 % CI 0·93, 2·22,Pfor trend0·030) when comparing the highestv.the lowest quartile of potato consumption. In the sex-specific analyses, significant associations were found for females (HR 2·00; 95 % CI 1·07, 3·72,Pfor trend0·020), but not for males (HR 1·01; 95 % CI 0·56, 1·84,Pfor trend0·34). In addition, we explored the associations by spline regression, and the absence of dose–response effects was confirmed. In this study, high potato consumption was not consistently associated with a higher risk of pancreatic cancer. Further studies with larger populations are needed to explore the possible sex difference.

Prognostic Value of m6A RNA Methylation Modulators and Potential Clinical Application in Pancreatic Cancer

2020 ◽  
Author(s):  
Lianzi Wang ◽  
Huimin Li ◽  
Tao Li ◽  
Huihui Wang ◽  
Xuemei Li ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
High Risk ◽  
Pancreatic Adenocarcinoma ◽  
Risk Score ◽  
Prognostic Indicator ◽  
Gene Set Enrichment Analysis ◽  
Wilcoxon Test ◽  
Rna Methylation ◽  
Incidence And Mortality ◽  
M6a Rna Methylation

Abstract Background m6A is the most prevalent and abundant form of mRNA modification and plays a dual role in cancer development. The high incidence and mortality of pancreatic cancer are critical obstacles worldwide. In this study, we investigated the function of m6A RNA methylation modulators in pancreatic cancer. Methods Expression of 13 m6A RNA methylation modulators and clinical data from patients with pancreatic adenocarcinoma were obtained from TCGA database. Differences in the expression of 13 m6A RNA methylation modulators between tumour (n = 178) and healthy (n = 4) samples were compared by Wilcoxon test. LASSO Cox regression was used to select m6A RNA methylation modulators for analysis of the relationship between expression and clinical characteristics by univariate and multivariate regression. The pathways of the m6A RNA methylation modulators were examined by gene set enrichment analysis (GSEA) and we found enrichment in chemokine, ribosome, and mTOR signalling pathways. Results WTAP had a low expression in tumour samples compared with healthy samples. Furthermore, our analyses revealed that the m6A RNA methylation modulators YTHDF1, ALKBH5, METTL3, METTL14, and KIAA1429 correlated with high-risk patients, resulting in an elevated risk score and a lower overall survival. High-risk score correlated with clinical characteristic and was an independent prognostic indicator for pancreatic adenocarcinoma. The pathways involved were identified by GSEA to explore the potential mechanism of action. Conclusion Modulators involved in m6A RNA methylation were associated with the development of pancreatic cancer. A risk score based on the expression of YTHDF1, ALKBH5, METTL3, METTL14, and KIAA1429 may be an independent prognostic indicator.

Management of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

2019 ◽  
Author(s):  
Francis Igor Macedo ◽  
Danny Yakoub ◽  
Vikas Dudeja ◽  
Nipun B. Merchant
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
The United States ◽  
Locally Advanced Pancreatic Cancer ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer ◽  
Number Of Patients

The incidence of pancreatic cancer continues to rise, and it is now the third-leading cause of cancer-related deaths in the United States. Only 15 to 20% of patients are eligible to undergo potentially curative resection, as most tumors are deemed unresectable at the time of diagnosis because of either locally advanced disease or distant metastases. Improvements in preoperative CT imaging have enabled better determination of the extent of disease and allowed for better operative planning. Based on their relationship to the surrounding vasculature and structures and presence or absence of distant disease, pancreatic tumors are classified into four categories: resectable, borderline resectable pancreatic cancer (BRPC), locally advanced pancreatic cancer (LAPC), and metastatic. With the recent advent of more effective chemotherapy regimens, efforts have focused on using neoadjuvant therapy approaches to increase the likelihood of achieving an R0 in patients with BRPC and possibly convert unresectable, locally advanced tumors to potentially resectable tumors. Response with neoadjuvant therapy regimens has resulted in increased number of patients eligible for resection, many times requiring vascular resection. Herein, we describe recent changes in the classification, important surgical and pathologic considerations and updated multimodal therapeutic options in the complex management of BRPC and LAPC.  This review contains 5 figures, 2 tables, and 78 references. Key Words: borderline resectable pancreatic cancer, CA 19-9, FOLFIRINOX, locally advanced pancreatic cancer, nab-paclitaxel, neoadjuvant chemotherapy, pancreatectomy, portal vein resection, radiation therapy, gemcitabine

scholarly journals Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question

2020 ◽  
Vol 93 (1106) ◽  
pp. 20190627
Author(s):  
Marta Scorsetti ◽  
Tiziana Comito ◽  
Davide Franceschini ◽  
Ciro Franzese ◽  
Maria Giuseppina Prete ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Pancreatic Adenocarcinoma ◽  
Local Treatment ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Free Survival ◽  
Number Of Patients ◽  
Clinical Considerations

Objectives: To evaluate the role of stereotactic body radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer. Methods: Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression-free survival (PFS), and overall survival (OS). Results: From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). LC at 1 and 2 years were 88.9% (95% CI 73.2–98.6) and 73.9% (95% CI 50–87.5), respectively. Median LC was 39.9 months (95% CI 23.3—not reached). PFS rates at 1 and 2 years were 21.9% (95% CI 10.8–35.4) and 10.9% (95% CI 3.4–23.4), respectively. Median PFS was 5.4 months (95%CI 3.1–11.3). OS rates at 1 and 2 years were 79.9% (95% CI 63.7–89.4) and 46.7% (95% CI 29.6–62.2). Median OS was 23 months (95%CI 14.1–31.8). Conclusions: Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results. Advances in knowledge: Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT

Sign in / Sign up

Export Citation Format

Share Document